The new expanded offering leverages the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China, including amyloid, tau, and other targets. A dedicated team of neuroscientists and project managers have led multiple trials in China to date. PET imaging has supported novel studies for Alzheimer's disease (AD) and other neurodegenerative diseases. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario's global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.JanuClario, a technology company that delivers the leading endpoint technology solutions for clinical trials, and XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, have expanded their partnership to deliver PET imaging clinical trials for testing novel therapeutics in China.Ĭlario, formerly ERT and Bioclinica, and XingImaging joined forces in 2018 to support multi-center clinical trials requiring PET for eligibility and drug efficacy evaluation. Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. Through experience gained from over 19,000 clinical trials delivered in support of 870 regulatory approvals, Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. The new name and brand identity became effective on Nov. 3, 2021.Ĭlario delivers the leading endpoint technology solutions for clinical trials. ![]() Between 20 alone, Clario supported 70 percent of all Federal and Drug Administration (FDA) approvals. Since 1990, Clario has completed more than 19,000 clinical trials and contributed to 870 regulatory approvals. Our purpose is clear – we transform lives by unlocking better evidence." ![]() "We have combined decades of scientific expertise and unrivaled global scale to create the broadest endpoint technology platform poised to expedite the clinical trial process, simplify trial experiences and unlock composite endpoints. "Clario is much more than the merger of two companies," said CEO Joe Eazor. Trial Anywhere™ offers sites and sponsors more clinical trial options, empowers patient choice, and provides the means to create diversity within clinical trials improving health equity. ![]() Only Clario can deliver Trial Anywhere™, the ability to execute decentralized, hybrid and site-based clinical trials by deploying technology while maintaining the precision and reliability of evidence. Led by over 200 therapeutic area experts, Clario delivers innovative therapeutic area technology solutions to meet clinical trial objectives. ![]() Clario's scientific, regulatory, engineering and operations expertise guides clinical trial partners through every phase of clinical development. With almost 50 years of experience, Clario has mastered generating the reliable evidence needed to bring new medicines, medical devices and therapies to market. Clario is committed to innovating the future of clinical trials through technology and having a positive impact on global healthcare. In doing so, Clario empowers its partners to transform lives. 3, 2021 /PRNewswire/ - ERT, the global clinical endpoint technology leader, today announced that following its early Q2 merger with Bioclinica, a technological and scientific leader in medical imaging, the combined company is renamed Clario.Ĭlario is a technology company that generates the richest clinical evidence by fusing scientific expertise and global scale into the broadest endpoint technology platform.
0 Comments
Leave a Reply. |